<DOC>
	<DOCNO>NCT01307579</DOCNO>
	<brief_summary>This randomized phase III trial study caspofungin acetate see work compare fluconazole prevent invasive fungal infection patient acute myeloid leukemia undergo chemotherapy . Caspofungin acetate fluconazole may help prevent fungal infection cause chemotherapy . It yet know whether fluconazole effective caspofungin acetate prevent fungal infection patient acute myeloid leukemia undergo chemotherapy .</brief_summary>
	<brief_title>Caspofungin Acetate Fluconazole Preventing Invasive Fungal Infections Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine prophylaxis caspofungin ( caspofungin acetate ) administer period neutropenia follow chemotherapy acute myeloid leukemia ( AML ) associate low incidence proven probable invasive fungal infection ( IFI ) compare fluconazole . SECONDARY OBJECTIVES : I . To determine prophylaxis caspofungin result low incidence proven probable case invasive aspergillosis ( IA ) compare fluconazole . ( Clinical ) II . To determine prophylaxis caspofungin result improve survival compare fluconazole . ( Clinical ) III . To determine prophylaxis caspofungin result less empiric antifungal therapy compare fluconazole . ( Clinical ) IV . To determine sensitivity , specificity , positive negative predictive value biweekly galactomannan ( GM ) beta-D glucan test diagnose IFI . ( Biological ) V. To test association single nucleotide polymorphism ( SNPs ) gene involve innate immunity proven probable IFI . ( Biological ) VI . To develop predictive model IFI use SNP gene involve immunity clinical covariates . ( Biological ) OUTLINE : Patients randomize 1 2 treatment arm . ARM I : Patients receive caspofungin acetate intravenously ( IV ) 1 hour daily ( QD ) begin within 24-72 hour follow last dose chemotherapy course continue absolute neutrophil count ( ANC ) &gt; 100-500/uL follow nadir next chemotherapy course begin . ARM II : Patients receive fluconazole IV 1-2 hour orally ( PO ) QD begin within 24-72 hour follow last dose chemotherapy course continue ANC &gt; 100-500/uL follow nadir next chemotherapy course begin . In arm , treatment continue absence invasive fungal infection disease progression . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Leukemia , Monocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Erythroblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Megakaryoblastic , Acute</mesh_term>
	<mesh_term>Caspofungin</mesh_term>
	<mesh_term>Echinocandins</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<criteria>Patients must one follow diagnosis and/or treatment plan : Newly diagnose de novo AML First subsequent relapse AML Secondary AML Treatment institutional standard AML therapy without AML ( example , myelodysplastic syndrome , bone marrow blast &gt; 5 % biphenotypia ) Note : Patients history prolonged antifungal therapy ( example , relapse AML ) eligible Creatinine clearance radioisotope glomerular filtration rate ( GFR ) &gt; = 70 mL/min/1.73 m^2 OR serum creatinine base age/gender follow : = &lt; 0.4 mg/dL ( age 1 month &lt; 6 month ) = &lt; 0.5 mg/dL ( age 6 month &lt; 1 year ) = &lt; 0.6 mg/dL ( age 1 &lt; 2 year ) = &lt; 0.8 mg/dL ( age 2 &lt; 6 year ) = &lt; 1 mg/dL ( age 6 &lt; 10 year ) = &lt; 1.2 mg/dL ( age 10 &lt; 13 year ) = &lt; 1.4 mg/dL ( females age &gt; = 13 year ) = &lt; 1.5 mg/dL ( male age 13 &lt; 16 year ) = &lt; 1.7 mg/dL ( male age &gt; = 16 year ) Total bilirubin = &lt; 1.5 x upper limit normal ( ULN ) age Serum glutamic oxaloacetic transaminase ( SGOT ) ( aspartate aminotransferase [ AST ] ) serum glutamate pyruvate transaminase ( SGPT ) ( alanine aminotransferase [ ALT ] ) &lt; 2.5 x ULN age All patient and/or parent legal guardian must sign write informed consent Patients follow diagnosis eligible : Acute promyelocytic leukemia ( APL ) Down syndrome Juvenile myelomonocytic leukemia ( JMML ) Patients documented history invasive fungal infection ( IFI ) within previous 30 day eligible Patients history echinocandin fluconazole hypersensitivity eligible Patients receive treatment IFI eligible Female patient childbearing age must negative pregnancy test Patients must agree use effective birth control method Lactating patient must agree nurse child trial</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>